Dermata Therapeutics Reports Q1 Loss

Dermata Therapeutics posts Q1 GAAP EPS of -$0.48 Dermata Therapeutics reported a Q1 GAAP EPS of -$0.48, beating expectations by $0.05. The company's cash and cash equivalents decreased to $6.9 million as of March 31, 2026, from $7.5 million as of December 31, 2025.